The generic drug segment was hot in 2015, but investor interest has cooled considerably in 2017. Here’s a look at the recent M&A activity.
Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced […]
To fulfill a condition of its $40.1 billion acquisition of Allergan‘s (NYSE: AGN) U.S. generics business, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) agreed to sell a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms to Impax Laboratories Inc. (NASDAQ: IPXL). The $586 million price includes the return to Impax of […]
With six acquisitions already on the books in 2015, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would pay $2.3 billion for Representaciones e Investigaciones Médicas (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico. Also associated with this deal is a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin […]
Teva Pharmaceutical (NYSE: TEVA) has had a busy year, making four divestitures and four acquisitions. Last week it tipped the balance in favor of acquisitions, with the purchase of privately held Gecko Health Solutions in Cambridge, Massachusetts. Gecko’s CareTRx™ platform is a novel cloud-based solution designed to simplify chronic respiratory disease management, connecting patients and caregivers […]
Sure, you’ve heard about Teva Pharmaceutical Industries’ (NYSE: TEVA) $40.5 billion acquisition of Allergan Generics (NYSE: AGN), announced on July 27. Less hyped was Teva Pharmaceuticals USA’s sale of 22 previously marketed generic drug brands to ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) for $25 million and a percentage of future gross profits from product sales. Earlier […]
The fireworks didn’t end on the Fourth of July, at least for the health care M&A market. Preliminary data shows deal volume rose 16% to 121 deals, compared with June’s 104 deals. Thanks to the mega-deals among health insurers and generic drug makers, deal value was approximately $166.6 billion, up 883% over June’s $16.9 billion. […]
Last week we noted that April was a slow month for healthcare deals. Then we checked our database, DealSearchOnline.com, and discovered there have been 19 billion-dollar deal announcements already in 2015, through May 8th, with a combined total of $103.6 billion. The total for the entire year is about to top $120 billion, on 487 […]